Incidence and Prevalence of Sexual Dysfunction in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015.
Marita P McCabe, Ira D Sharlip, Ron Lewis...
https://pubmed.ncbi.nlm.nih.gov/26953829/Actively Recruiting
Led by University Hospitals Cleveland Medical Center · Updated on 2026-07-23
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying sexual dysfunction in breastfeeding postpartum patients, focusing on whether vaginal estrogen cream improves sexual function compared to not using it. This study involves breastfeeding patients who are between 6 weeks and 6 months postpartum and aims to evaluate the effects of vaginal estrogen on sexual health during this period. Participants are randomly assigned to one of two groups one group uses vaginal estrogen inserts, and the other uses a vaginal moisturizer. The vaginal estrogen is given as softgel inserts daily for two weeks and then twice weekly for ten weeks. The vaginal moisturizer is used on the same schedule. Treatments are delivered to participants homes, and usage instructions are provided. Weekly questions about breastfeeding, sexual activity, pain, and treatment use are sent during the 12-week study period. Participants complete questionnaires at baseline, 6 weeks, and 12 weeks, covering sexual function, anxiety, depression, urinary distress, vaginal health, and sexual distress. Responses indicating depression or anxiety are reviewed by a physician for safety. Additional questionnaires at 6 months and 1 year assess long-term benefits. After the 12-week period, no more study treatments are given, and participants who wish to continue treatment are referred to their care providers. The primary outcome measured is the Female Sexual Function Index score up to 12 weeks into the study.
CONDITIONS
Postpartum Vaginal Estrogen for Breastfeeding Patients
S
Susan D Wherley, MD
R
Rosemary Brewka
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospitals Cleveland Medical Center
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Vaginal Estradiol (Imvexxy) | Vaginal Moisturizer (vitamin E–based) |
|---|---|---|
| What it is | Imvexxy is a low-dose vaginal estradiol soft-gel insert, used locally to treat vaginal symptoms. | A non-hormonal, vitamin E–based vaginal moisturizer containing hydrogenated coconut and palm oils. |
| Role in trial | Evaluated as the investigational therapy for postpartum sexual dysfunction and vaginal atrophy during breastfeeding. | Active comparator arm; standard non-hormonal moisturizer therapy for vaginal symptoms. |
| Primary use | Treats vulvovaginal symptoms such as dryness and discomfort in patients who are postpartum and breastfeeding. | Moisturizes and relieves vaginal dryness and discomfort in postpartum breastfeeding women. |
| How it is given or performed | Vaginal estradiol is given as a soft-gel capsule inserted locally into the vagina. | Moisturizer is applied locally to the vaginal area as per study protocol instructions. |
| Evidence status | Local estradiol has proven efficacy for reducing vaginal dryness and improving sexual function in postmenopausal women, with some data supporting improvement in vaginal symptoms in breastfeeding women. | Non-hormonal vaginal moisturizers help relieve dryness and discomfort, but may be less effective than local estrogen for long-term improvement of atrophic symptoms. |
| Important risks | Local absorption of estradiol is possible. Systemic absorption is low but may occur, and safety in breastfeeding/postpartum women is still under active investigation for potential hormonal effects. | Generally considered safe with minimal side effects such as mild local irritation. |
| Important limitations | Most studies focus on postmenopausal women; evidence for safety and efficacy in breastfeeding postpartum women is limited and under investigation. | Provides symptom relief but does not address underlying atrophy; may require continuous use for effects to be maintained. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive either vaginal estrogen inserts or vaginal moisturizer to use at home. They use the treatment nightly for two weeks and then twice weekly for ten weeks. Weekly questionnaires about breastfeeding, sexual activity, vaginal pain, and treatment use are sent.
Weekly contacts and questionnaires
Duration - Up to 1 year after treatment
Participants complete additional questionnaires at 6 months and 1 year to assess long-term effects. Those wishing to continue treatment after the study are referred to their postpartum care providers.
Questionnaires at 6 months and 1 year
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Marita P McCabe, Ira D Sharlip, Ron Lewis...
https://pubmed.ncbi.nlm.nih.gov/26953829/Ginger D Constantine, James A Simon, James H Pickar...
https://pubmed.ncbi.nlm.nih.gov/27922936/Sanjay K Agarwal, Julie Kim, Lisa M Korst...
https://pubmed.ncbi.nlm.nih.gov/25565323/J Suckling, A Lethaby, R Kennedy
https://pubmed.ncbi.nlm.nih.gov/17054136/Lina Maria Matthies, Markus Wallwiener, Christof Sohn...
https://pubmed.ncbi.nlm.nih.gov/30327862/Jan L Shifren, Brigitta U Monz, Patricia A Russo...
https://pubmed.ncbi.nlm.nih.gov/18978095/Figen Alp Yılmaz, Ayşe Şener Taplak, Sevinç Polat
https://pubmed.ncbi.nlm.nih.gov/31298557/Megan Krause, Thomas L Wheeler, Holly E Richter...
https://pubmed.ncbi.nlm.nih.gov/22453284/Brennan C Kahan, Vipul Jairath, Caroline J Doré...
https://pubmed.ncbi.nlm.nih.gov/24755011/Mojdeh Banaei, Azam Moridi, Sareh Dashti
https://pubmed.ncbi.nlm.nih.gov/30515059/University Hospitals Cleveland Medical Center
Lead Sponsor